Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,317
  • Shares Outstanding, K 13,428
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,380 K
  • 60-Month Beta 1.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -71.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.87 +14.37%
on 07/14/20
5.95 -6.39%
on 07/20/20
+0.28 (+5.29%)
since 07/02/20
3-Month
4.80 +16.04%
on 05/15/20
6.78 -17.85%
on 06/23/20
+0.29 (+5.49%)
since 05/05/20
52-Week
3.59 +55.15%
on 03/18/20
44.90 -87.59%
on 09/23/19
-15.21 (-73.20%)
since 08/05/19

Most Recent Stories

More News
Enlivex Announces a new publication "Apoptotic cell therapy for cytokine storm associated with acute severe sepsis" in Cell Death & Disease, a Nature Research Journal

- Data show a 90% decrease in mortality with Allocetra treatment in a murine cecal ligation and puncture severe sepsis model

ENLV : 5.57 (+2.01%)
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy

Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issued a notice of allowance for a patent application covering ALLOCETRA, the...

ENLV : 5.57 (+2.01%)
Enlivex Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday,...

ENLV : 5.57 (+2.01%)
Enlivex Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Annual Meeting

- Exploratory endpoint analyses demonstrated Allocetra's potential therapeutic effect in resolving cytokine storms in patients with heterogenous pathologies

ENLV : 5.57 (+2.01%)
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that an investigator-initiated multi-center Phase II clinical trial of Allocetra (formerly referred to...

ENLV : 5.57 (+2.01%)
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the Israel Innovation Authority (IIA) selected the Company's planned COVID-19 and sepsis clinical...

ENLV : 5.57 (+2.01%)
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis

- Final Analysis Comparing 10 Allocetra-Treated Patients with 37 Matched Controls Showed Significant Positive Responses in State of Organ Failure, ICU Hospitalization and Mortality in a Highly Fragile...

ENLV : 5.57 (+2.01%)
Israel Patent Office Grants New Patent Covering Enlivex's Allocetra Immunotherapy Treatment

Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israel Patent Office granted a new patent (#239236) covering ALLOCETRA, the company's immunotherapy candidate....

ENLV : 5.57 (+2.01%)
Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain accredited and healthcare-focused...

ENLV : 5.57 (+2.01%)
Enlivex Therapeutics Confirms Public Statements Made by the Head of Israel Economic and Commercial Mission to South Korea

Regarding Submission of Proposal to the Korean Authorities for Potential Use of Allocetra as Treatment of Patients with Coronavirus Disease (COVID-19) Patients Admitted to ICU

ENLV : 5.57 (+2.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade ENLV with:

Business Summary

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome)...

See More

Key Turning Points

2nd Resistance Point 5.75
1st Resistance Point 5.66
Last Price 5.57
1st Support Level 5.48
2nd Support Level 5.40

See More

52-Week High 44.90
Fibonacci 61.8% 29.12
Fibonacci 50% 24.25
Fibonacci 38.2% 19.37
Last Price 5.57
52-Week Low 3.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar